Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?

Autor: Lübbers, Katharina, Pavlychenko, Mykola, Wald, Theresa, Wiegand, Susanne, Dietz, Andreas, Zebralla, Veit, Wichmann, Gunnar

Background: The landmark EXTREME trial established cisplatin, 5-fluorouracil and cetuximab (PFE) as first-line chemotherapy (1L-ChT) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). We were interested in outcome differences

Externí odkaz: https://ul.qucosa.de/id/qucosa%3A84395
https://ul.qucosa.de/api/qucosa%3A84395/attachment/ATT-0/

Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?

Autor: Lübbers K; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Pavlychenko M; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Wald T; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Wiegand S; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Dietz A; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Zebralla V; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany., Wichmann G; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leipzig, Leipzig, Germany.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Jul 20; Vol. 11, pp. 715297. Date of Electronic Publication: 2021 Jul 20 (Print Publication: 2021).